ClinicalTrials.gg
CompletedNCT07848711Updated Oct 2, 2026

Comparison of Two Expansion Techniques for Horizontal Bone Deficiency

An interventional study of Bone expansion and implant placement with crest split and Bone expansion and implant placement with specifically design drills in Horizontal Alveolar Bone Loss, Implant Therapy and Primary Stability of the Implants, sponsored by Ege University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Ege University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 2 years 9 months after the study started (first participant enrolled Dec 2023, registered Sep 2026).
Updated Oct 2, 2026Primary outcomes revisedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Alveolar Bone Loss with a site in Turkey — 8 open to participants now, 10 under way, none of them phase 3. Alveolar Bone Loss · Turkey.

Enrollment
14th of 20
20 · median 30
Started
2023
with 5 others
No phase
18 of 33
4 open now
Registered
31st of 33
by date
Lead sponsor
3 of 33
Ege University

Among the 33 studies in Alveolar Bone Loss with a site in Turkey, this one is the 14th largest by enrollment of the 20 interventional ones that give a count, is one of 6 that started in 2023, is one of 18 with no phase, and was the 31st registered.

Alveolar Bone Loss

320 studies on the registry are indexed under Alveolar Bone Loss; 79 are open to participants now.

Browse Alveolar Bone Loss studies →

Open to participants now

8 of the 33 studies in Alveolar Bone Loss with a site in Turkey are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 47 Alveolar Bone Loss studies recruiting now, 19 (40%) set no upper age limit and 22 (47%) stop at 75 or younger; 4 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Alveolar Bone Loss with a site in Turkey, or all of them as a file.
02

Study summary

This was a prospective, randomized clinical trial conducted at the Department of Oral and Maxillofacial Surgery, Ege University. Patients exhibiting horizontal bone insufficiency (residual crest width \< 4 mm) in the posterior mandible received dental implants with two techniques: osseodensification or crest split. The investigator compared to clinical and radiological outcomes of these techniques.

Read the detailed description

This prospective, parallel-group randomized clinical trial was conducted at the Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Ege University, İzmir, Turkey, between February 2021 and August 2023.Patients exhibiting horizontal bone insufficiency (residual crest width \< 4 mm) in the posterior mandible received dental implants with two techniques. The primary predictor variable was the ridge expansion technique: Osseodensification (Group 1, n=10 patients, 21 implants) or Crest Split (Group 2, n=10 patients, 25 implants). primary outcome variables were primary stability. The secondary outcome variables were clinical bone expansion, intraoperative/postoperative complications, marginal bone level, plaque accumulation, and bleeding on probing.

03

Conditions studied

  • Horizontal Alveolar Bone Loss
  • Implant Therapy
  • Primary Stability of the Implants
  • Complication
  • Periodontal Health

Browse trials for

Keywords

  • alveolar ridge deficiency
  • crest split
  • expansion
  • implant
  • complication
  • radiological assessment
  • marginal bone level
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • a residual horizontal alveolar crest width of less than 4 mm
  • clinical indication for at least two implants
  • good systemic health

Exclusion criteria

Exclusion Criteria:

  • patients requiring vertical augmentation
  • tooth extraction prior or peri-surgery
  • presence of acute local infection or pathology at the operative site
  • allergy to titanium, anesthetics, or surgical materials
  • pregnancy or lactation
  • history of bisphosphonate or antiresorptive use
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
20 participants (actual)

Study arms

  • Active comparator
    Crest Split

    Bone expansion and implant placement with crest split

    Procedure: Bone expansion and implant placement with crest split

  • Experimental
    Drill system

    Bone expansion and implant placement with specifically design drills

    Procedure: Bone expansion and implant placement with specifically design drills

Interventions

  • ProcedureBone expansion and implant placement with crest split

    Bone expansion was provided with chisel and mullet. Implant was inserted following expansion.

  • ProcedureBone expansion and implant placement with specifically design drills

    Bone expansion was provided with implant drills. Implant was inserted following expansion.

06

What researchers measure

Primary outcomes

  1. Mean of implant stability quantity (ISQ) value

    Calculation of ISQ value: Measurement for each implant using resonance frequency analysis (RFA)

    Time frame: At surgery

  2. Mean of torque value

    Calculation of torque value: Measurement for each implant using a ratchet and torque wrench

    Time frame: At surgery

Secondary outcomes

  1. Marginal bone level

    Change in peri-implant bone level

    Time frame: through study completion, ana average of 2 year

  2. Complication

    Number of operative and postoperative complications

    Time frame: through study completion, an average of 2 year

  3. Peri-implant health

    Calculation of bleeding on probing and plaque accumulation. Bleeding on probing: Assessment of bleeding presence/absence using a periodontal probe. Plaque accumulation: Assessment of plaque presence/absence using a modified plaque index.

    Time frame: at 12 months

07

Study locations

1 site
  • Ege University
    Izmir, Bornova 35100, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2023 to primary completion in Jun 2024, 6 months.

Of 169 non-industry interventional studies with no phase under Alveolar Bone Loss, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 30. This study's 6 months is below that.

Counting every sponsor, half of 169 studies reached it within 18 months; a quarter within 11 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2026
First posted
Sep 30, 2026
StartActual
Dec 1, 2023
Primary completionActual
Jun 1, 2024
CompletionActual
Sep 2, 2024
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary outcomes
1 edited, 1 description edited
What changed in the outcomes
  • EditedMean of implant insertionstability quantity (ISQ) valueTime frame: At surgery
  • DescriptionMean of torque value: how it is measured was reworded
Oct 2, 2026
Secondary outcomes
1 description edited
What changed in the outcomes
  • DescriptionPeri-implant health: how it is measured was reworded
Oct 2, 2026
Registered
First appeared on the registry
Sep 30, 2026
Show all 2 updates
  1. Oct 2, 2026
    Primary outcomes 1 edited, 1 description edited
    What changed in the outcomes
    • EditedMean of implant insertionstability quantity (ISQ) valueTime frame: At surgery
    • DescriptionMean of torque value: how it is measured was reworded
    Secondary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionPeri-implant health: how it is measured was reworded
  2. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07848711
Lead sponsor
Ege University
Responsible party
Gözde Işık (Associate Professor, Ege University) — Principal investigator
First posted
Sep 30, 2026
Start date
Dec 1, 2023
Primary completion
Jun 1, 2024
Completion
Sep 2, 2024
Last update
Oct 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion